Welcome to our dedicated page for Adverum Biotech news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotech stock.
Adverum Biotechnologies, Inc. (ADVM) generated a stream of news as a clinical-stage gene therapy company focused on highly prevalent ocular diseases, particularly neovascular or wet age-related macular degeneration (wet AMD). Company releases consistently describe Adverum’s goal of establishing intravitreal gene therapy as a new standard of care, using durable, single-administration treatments to preserve sight and potentially prevent blindness.
News coverage for ADVM has centered on the development of its lead gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly ADVM-022). Updates have included milestones in the pivotal Phase 3 ARTEMIS trial for wet AMD, such as initiation, screening progress, and the completion of target enrollment of 284 patients, as reported in SEC filings and press releases. Additional articles have highlighted long-term follow-up data from earlier studies like OPTIC and LUNA, as well as scientific presentations on Ixo-vec biodistribution and aflibercept expression in the eye.
Investors following ADVM-related news can also see announcements about regulatory designations for Ixo-vec, including Fast Track and RMAT status from the U.S. FDA, PRIME designation from the European Medicines Agency, and the Innovation Passport in the UK. Corporate updates have covered financing activities, inducement equity grants under the 2017 Inducement Plan, and participation in ophthalmology conferences.
A major theme in later news is the strategic transaction with Eli Lilly and Company. Releases dated October and December 2025 detail Lilly’s tender offer to acquire all outstanding Adverum shares for cash plus a non-tradable contingent value right (CVR), and the subsequent expiration and completion of the tender offer with all conditions satisfied. This news page therefore serves both as a record of Adverum’s clinical and corporate developments and as an archive of announcements leading up to and including its acquisition by Lilly.
Adverum Biotechnologies (Nasdaq: ADVM) announced the appointment of Jon Williams, Ph.D., as vice president of clinical affairs, effective immediately. With 25 years of experience in drug development and regulatory strategies, Dr. Williams will enhance the clinical development of the novel gene therapy candidate ADVM-022. He previously held significant roles at Bausch Health and Aerie Pharmaceuticals, contributing to multiple successful product developments. Additionally, Dr. Williams received a stock option grant of 100,000 shares, vesting over four years, contingent on his continued service.
Adverum Biotechnologies (Nasdaq: ADVM) announces leadership changes as Leone Patterson departs as president and CFO after five years. Christopher J. DeRespino takes over as acting CFO, previously serving as chief business officer, and Peter Soparkar has been appointed COO. Both appointments are effective immediately. The company emphasizes continued focus on patient safety as they prepare to update on the ADVM-022 program in August. Adverum is committed to addressing unmet medical needs in ocular and rare diseases through innovative gene therapies.
Adverum Biotechnologies (Nasdaq: ADVM) announced the appointments of Julie Clark, M.D. as chief medical officer and Brigit Riley, Ph.D. as chief scientific officer, effective immediately. Both leaders will report to Laurent Fischer, M.D.. Their extensive backgrounds in gene therapy will enhance Adverum's efforts in the ADVM-022 program, which focuses on addressing patient safety and expanding the pipeline for ocular diseases. An inducement grant was provided to Dr. Riley, allowing her to purchase 450,000 shares of common stock, with details outlined under Nasdaq regulations.
The Sonic Fund II, L.P., holding approximately 6.8% of Adverum Biotechnologies' common stock (NASDAQ: ADVM), issued a statement on the preliminary voting results from the 2021 Annual Meeting of Stockholders. Sonic expressed gratitude for stockholder support for change and highlighted that proxy advisory firms ISS and Glass Lewis recommended voting for its nominees, citing serious shortcomings in the Company's approach, particularly regarding the ADVM-022 development. Sonic emphasized the need for Adverum to enhance Board accountability and refocus on addressing critical patient needs.
Adverum Biotechnologies (Nasdaq: ADVM) announced the preliminary results of its 2021 Annual Meeting of Stockholders. Shareholders re-elected directors Dawn Svoronos, Reed V. Tuckson, M.D., and Thomas Woiwode, Ph.D., ratified Ernst & Young LLP as independent auditors, and approved executive compensation on an advisory basis. The Board acknowledged shareholder support and feedback while emphasizing patient safety in the ongoing ADVM-022 program. Final voting results will be reported in a Form 8-K submitted to the SEC.
Sonic Fund II, L.P. owns about 6.8% of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) and expresses concerns about stockholder impressions regarding management's potential resignation if Sonic's nominees join the Board. Sonic urges stockholders to disregard these fears unless publicly clarified by Adverum's management. The Fund emphasizes the importance of fiduciary duties under Delaware law and advocates for its independent nominees to work collaboratively with existing Board members to enhance stockholder value and improve patient care.
The Sonic Fund II, L.P., holding 6.8% of Adverum Biotechnologies (NASDAQ: ADVM), urges shareholders to vote for its nominees at the 2021 Annual Meeting on May 12, 2021. Sonic criticizes Adverum for mismanaging the development of ADVM-022, a gene therapy for wet AMD, resulting in a significant drop in stock price (~60% after a serious adverse reaction). Leading proxy advisory firms recommend Sonic's nominees for change in the Board, stressing the need for better oversight and expertise to advance ADVM-022's development and restore shareholder value.
Adverum Biotechnologies Inc. (Nasdaq: ADVM) announced that Jean Bennett, a nominee for its Board of Directors, has opted to withdraw her candidacy ahead of the Annual Meeting scheduled for May 12, 2021. This decision was communicated to CEO Laurent Fischer on May 6, following Dr. Bennett's discomfort with the role. Adverum emphasized its commitment to patient safety in the ongoing review of its ADVM-022 program, aimed at treating serious ocular diseases. The company continues to prioritize this clinical development while the situation unfolds with Sonic Fund II.
Adverum Biotechnologies (Nasdaq: ADVM) reported its Q1 2021 financial results on May 6, highlighting a net loss of $28.4 million, or $0.29 per share. License revenue reached $7.5 million, a significant increase from zero in Q1 2020. Research and development expenses rose to $20 million due to heightened clinical trial costs. The company is reviewing safety data linked to its ADVM-022 gene therapy program following a serious adverse event. As of March 31, 2021, cash reserves totaled $404 million, down from $429.7 million at year-end 2020, prompting a reassessment of timelines and funding priorities.
The Sonic Fund II, L.P., owning about 6.8% of Adverum Biotechnologies (NASDAQ: ADVM), announced ISS's recommendation for stockholders to vote for its nominees – Jean Bennett, Jodi Cook, and Herbert Hughes – in the upcoming 2021 Annual Meeting on May 12, 2021. ISS highlighted Adverum's significant stock underperformance, citing a 54.6% decline compared to peers. Concerns were raised about clinical trial safety and high director compensation. Sonic argues that change is crucial to restore investor confidence and governance independence amid financial challenges.